Development of a natural transmission model of COVID-19

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Total publications:3 publications

Grant number: MR/V036963/1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $260,069.16
  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Principal Investigator

    Dr. Stuart Dowall
  • Research Location

    United Kingdom
  • Lead Research Institution

    Department of Health and Social Care
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Disease models

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

For the assessment of interventions against COVID-19, there are currently no alternatives to the use of animal systems that fully recapitulate a whole functioning body system. The initial focus on in vivo models for COVID-19, based on experiences of establishing animal models for the pathogenic coronaviruses which cause SARS and MERS, were with ferret and non-human primate models. However, recent results from international laboratories working on SARS-CoV-2 have highlighted that hamsters show a more distinctive COVID19 disease with clinical signs associated with respiratory infection (rapid breathing, weight loss, ruffled fur). In addition to the clinical signs, hamsters have also been shown to shed SARS-CoV-2 and infect their naïve cage mates. Developing the means of establishing and investigating this natural challenge model will provide important and beneficial testing protocols that can be used evaluate prophylactic therapies and vaccines via a natural infection route under experimental conditions, within a carefully controlled containment level 3 (CL3) envelope. This capability will also enable investigations on transmissibility between animals and studies on different strains, including those SARS-CoV-2 viruses that may be engineered by molecular virology techniques to address questions on virus host interactions. Hamsters appear to offer a valuable disease model for COVID-19. Importantly, establishing the hamster model and associated techniques to evaluate interventions in the UK at the unique CL3 facilities of PHE-Porton, will also support a rapid intervention screening and in vivo research hub for the country on COVID-19. This will support UK industry and academia's research need's and evidence base to progress into clinical trials

Publicationslinked via Europe PMC

Use of a Preclinical Natural Transmission Model to Study Antiviral Effects of a Carbohydrate-Binding Module Therapy against SARS-CoV-2 in Hamsters.

Activity of a Carbohydrate-Binding Module Therapy, Neumifil, against SARS-CoV-2 Disease in a Hamster Model of Infection.

Development of a Hamster Natural Transmission Model of SARS-CoV-2 Infection.